Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Quarterly results
Inv. presentation
Auditor change

Evoke Pharma Inc (EVOK) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/12/2023 8-K Quarterly results
08/10/2023 8-K Quarterly results
Docs: "Investor Contact: Daniel Kontoh-Boateng DKB Partners Tel: 862-213-1398"
07/21/2023 8-K Quarterly results
05/26/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
05/11/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "EVOKE PHARMA, INC.",
"EVOKE PHARMA, INC. 2013 EMPLOYEE STOCK PURCHASE PLAN Article 1."
05/09/2023 8-K Other Events  Interactive Data
05/01/2023 8-K Quarterly results
04/20/2023 8-K Quarterly results
04/06/2023 8-K Other Events  Interactive Data
03/23/2023 8-K Other Events  Interactive Data
03/21/2023 8-K Quarterly results
Docs: "Evoke Pharma Reports Fourth Quarter and Full Year 2022 Financial Results Fiscal year 2022 net product sales from prescriptions increased by 179% to $2.5 million versus 2021 Patient enrollment increased by 149% compared with 2021 SOLANA BEACH, Calif., March 21, 2023 -- Evoke Pharma, Inc. , a specialty pharmaceutical company focused primarily on treatments for gastrointestinal diseases with an emphasis on GIMOTI® nasal spray, today announced its financial results for the fourth quarter and full year ended December 31, 2022, and recent corporate developments. “Evoke’s fiscal year 2022 was a period of tremendous growth and progress on several key fronts. Year-over-year revenues, new prescribers, prescription fills, and patient enrollments showed significant improvement in 2022 compared ..."
02/13/2023 8-K Quarterly results
01/30/2023 8-K Other Events  Interactive Data
11/30/2022 8-K Quarterly results
11/09/2022 8-K Quarterly results
09/20/2022 8-K Other Events  Interactive Data
08/26/2022 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
08/10/2022 8-K Quarterly results
06/08/2022 8-K Quarterly results
05/23/2022 8-K Quarterly results
05/20/2022 8-K Quarterly results
05/10/2022 8-K Quarterly results
04/28/2022 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
04/26/2022 8-K Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549"
03/08/2022 8-K Quarterly results
02/24/2022 8-K Quarterly results
02/17/2022 8-K Other Events  Interactive Data
02/02/2022 8-K Quarterly results
01/04/2022 8-K Other Events  Interactive Data
12/30/2021 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549"
11/10/2021 8-K Quarterly results
Docs: "Evoke Pharma Reports Third Quarter 2021 Financial Results"
10/20/2021 8-K Other Events  Interactive Data
09/29/2021 8-K Other Events  Interactive Data
08/12/2021 8-K Quarterly results
Docs: "Evoke Pharma Reports Second Quarter 2021 Financial Results Approximately 162% growth in product sales, 152% growth in prescriptions and 57% increase in new prescribers for Gimoti ® Extends cash runway into third quarter of 2022"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy